Vyriad closed a $25 million final tranche of its Series B financing, bringing the round to $85 million and funding first‑in‑human testing of VV‑169, the company’s in vivo CAR‑T candidate for relapsed or refractory multiple myeloma. The tranche supports IND‑enabling and early clinical work to deliver an engineered viral or vector approach to reprogramming T cells in situ. Vyriad positions VV‑169 as an in vivo CAR strategy that could simplify manufacturing and broaden patient access compared with autologous CAR‑T. Investors supplied the additional capital to accelerate clinical entry amid growing interest in off‑the‑shelf and in vivo cellular approaches.